Table 1 Summary of the clinical information of the 15 PC patients who participated in this study
Patient Characteristics | |
|---|---|
Total, N | 15 |
Age, yr, median (range) | 62 (49–73) |
PSA value at diagnosis, ng/mL, median (range) | 5.9 (1.04–29.48) |
Biopsy stage, N (%) | |
1c | 11 (73%) |
1a | 1 (7%) |
2b | 3 (20%) |
Biopsy Gleason Grade Group, N (%) | |
Grade Group 1 = 3 + 3 | 3 (20%) |
Grade Group 2 = 3 + 4 | 6 (40%) |
Grade Group 3 = 4 + 3 | 4 (27%) |
Grade Group 4 = 4 + 4 | 2 (13%) |
Surgery stage, N (%) | |
2a | 7 (47%) |
3a | 7 (47%) |
3b | 1 (6%) |
Surgery Gleason score, N (%) | |
Grade Group 2 = 3 + 4 | 10 (67%) |
Grade Group 3 = 4 + 3 | 4 (27%) |
Grade Group 5 = 4 + 5 | 1 (6%) |
Nodes, N (%) | |
Positive | 1 (7%) |
Negative | 12 (80%) |
Cannot access | 3 (13%) |
Surgical margins, N (%) | |
Positive | 3 (20%) |
Negative | 12 (80%) |
Adjuvant therapy, N (%) | |
ADT | 2 (13%) |
Radiation | 1 (7%) |
Cancer recurrence, N (%) | |
Salvage treatment | 1 (7%) |
Biochemical recurrence | 1 (7%) |